<DOC>
	<DOCNO>NCT01791465</DOCNO>
	<brief_summary>This pilot study evaluate effect anti-diabetic drug Bydureon ( exenatide extended-release formulation ) blood sugar level serum marker inflammation cohort 12 HIV-infected adult combination antiretroviral therapy ( cART ) untreated diabetes mellitus . Previous study show high level persistent systemic inflammation predict development cardiovascular metabolic diseases HIV-infected person cART ( group high risk atherosclerosis myocardial infarction ) . Bydureon demonstrate potent anti-inflammatory effect prior study non-HIV infected person , suggest agent may represent unique preferred medication treatment insulin resistance HIV-infected adult . The Investigators hypothesize short-term ( 16 week ) therapy Bydureon improve glucose tolerance significantly reduce circulate plasma level interleukin-6 ( IL-6 ) highly-sensitive C-reactive protein ( hsCRP ) , two biomarkers strongly implicate development cardiovascular metabolic diseases diabetic , HIV-infected , cART-treated adult .</brief_summary>
	<brief_title>Pilot Study Bydureon Treat Diabetes HIV-infected Adults</brief_title>
	<detailed_description>No information . This single-arm trial add additional anti-diabetic medication patient already know diabetic . The primary endpoint assess whether intervention reduce inflammation . There control arm .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Age ≥ 18 year Body mass index ≥ 25 kg/m2 Glycosylated hemoglobin ( A1C ) value ≥ 6.5 % OR fasting blood glucose ≥ 126 mg/dL On stable antiretroviral therapy ≥ 12 month ( fully suppress plasma HIV1 RNA level ) Negative serum pregnancy test ( female ) History pancreatitis Screening serum lipase value great equal 2 time upper limit normal ( ≥ 420 U/L ) History pancreatic cancer thyroid cancer patient , firstdegree relative , grandparent History Multiple Endocrine Neoplasia ( MEN ) 2 syndrome History gastroparesis , inflammatory bowel disease , and/or severe gastrointestinal disease Estimated glomerular filtration rate ( eGFR ) ≤ 50 mls/minute Documented history hypoglycemia ( blood glucose &lt; 40 mg/dl ) Active moderateheavy alcohol use ( 2 drinks/day ) &gt; 4 drink single 24 hour period On antidiabetic medication within 3 month enrollment On HMGCoA reductase inhibitor ( statin ) within 3 month enrollment Persons didanosine ( ddI ) and/or stavudine ( d4T ) contain cART ( due heighten risk pancreatitis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Diabetes</keyword>
</DOC>